Related Experiment Videos
[Meningeal carcinomatosis in solid tumors]
P Pfeiffer1, M R Tange, O Hansen
1Onkologisk afdeling R, Odense Universitetshospital.
Ugeskrift for Laeger
|October 30, 1995
Summary
Meningeal carcinomatosis (MC) is a late-stage cancer complication. Diagnosis requires neurological symptoms across the central nervous system, confirmed by lumbar puncture or MRI, with therapy focusing on quality of life.
Area of Science:
- Neuro-oncology
- Medical oncology
Background:
- Meningeal carcinomatosis (MC) is a rare but serious complication of non-hematological malignancies.
- It represents leptomeningeal spread of cancer cells, affecting the brain, cranial nerves, and spinal cord.
Observation:
- MC should be suspected in patients presenting with diffuse neurological symptoms affecting at least two compartments of the central nervous system.
- A discrepancy between clinical symptoms and objective neurological findings is a key indicator.
- Diagnostic confirmation relies on lumbar puncture and/or MRI with Gadolinium contrast.
Findings:
- Therapeutic strategies for MC are tailored to the specific tumor type, patient performance status, and overall disease status.
- Patients with good performance status and chemosensitive tumors may receive combined radiotherapy and chemotherapy.
- Median survival is limited, typically one to three months, and active treatment does not guarantee prolonged survival.
Implications:
- The primary goal of MC treatment is to improve the patient's quality of life rather than prolonging survival.
- Early suspicion and accurate diagnosis are crucial for initiating palliative care and supportive management.
- Further research may focus on novel therapeutic approaches to improve outcomes for patients with meningeal carcinomatosis.